Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2016—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies.
February 2016—The Clinical and Laboratory Standards Institute has published a new document titled “Management of Critical- and Significant-Risk Results (GP47-Ed1).” This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results.
February 2016—The Clinical and Laboratory Standards Institute has published a new document titled “Management of Critical- and Significant-Risk Results (GP47-Ed1).” This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results.
February 2016—Illumina launched its MiniSeq Sequencing System and, during a presentation at the J.P. Morgan Healthcare Conference, Jan. 11–14 in San Francisco, introduced the Infinium XT and previewed Project Firefly, which will lead to the commercialization of a new semiconductor-based sequencing system.
February 2016—Primera Trio from Primera Technology is a small, lightweight, portable all-in-one printer. Designed for nurses and doctors to print on demand at hospitals and home care facilities, Primera Trio prints, copies, and scans in full color or black monochrome from a unit that weighs 2.6 pounds and is about the size of a hardcover book.
February 2016—Enzo Life Sciences now offers EQ Quencher Dyes—amine-reactive quencher dyes that can be used for fluorescence resonance energy transfer (FRET) applications.
February 2016—Hamilton Storage introduced RackWare HD138 and HD60 high-density SBS-footprint racks for microtube and cryovial storage. Designed for use with Hamilton’s BiOS, SAM, and Verso sample management and storage systems, RackWare increases storage capacity by increasing the number of tubes that can be placed in an SBS-footprint rack. The racks can also be used to maximize storage in manual freezers.
February 2016—MDxHealth announced that data demonstrating the clinical potential of its urine-based epigenetic bladder cancer test AssureMDx, to aid urologists in the management of patients presenting with hematuria, has been published in The Journal of Urology.
February 2016—Epic Sciences announced a collaboration with University of Pennsylvania’s Abramson Cancer Center on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells at a single cell resolution, that are predictive of response to personalized cancer therapeutics.
February 2016—ScyTek Laboratories announced the availability of Pan Melanoma Cocktail antibody. This cocktail includes Tyrosinase, MART-1, and HMB45 clones.
